

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58924 A2

(51) International Patent Classification: **C07K 1/00**

(21) International Application Number: **PCT/DK01/00086**

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 00199 8 February 2000 (08.02.2000) DK
60/181,079 8 February 2000 (08.02.2000) US

(71) Applicant (for all designated States except US): **UPFRONT CHROMATOGRAPHY A/S** [DK/DK]; Lersø Parkallé 42, DK-2100 Copenhagen Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIHME, Allan, Otto, Fog** [DK/DK]; Furesøbakken 13, DK-3460 Birkerød (DK). **HANSEN, Marie, Bendix** [DK/DK];

Thurøvej 14, 1. th., DK-2000 Frederiksberg (DK). **BISGAARD-FRANTZEN, Hans** [DK/DK]; Sprogøvej 9, 3. th., DK-2000 Frederiksberg (DK). **RAHBEEK-NIELSEN, Henrik** [DK/DK]; Kirsebærlunden 1, DK-3460 Birkerød (DK).


(74) Agent: **PLOUGMANN, VINGTOFT & PARTNERS A/S**; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FR, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: **NOVEL RESIN MATERIALS AND THEIR USE FOR RECOVERING PROTEINS OR PEPTIDES**



(57) Abstract: Processes for recovering a target protein having milk clotting activity including chymosin, and other target proteins or peptides from an aqueous medium containing such a protein using a resin material comprising a solid support matrix and, covalently bound to the matrix, a target protein binding ligand selected from benzylamine or a derivative thereof; an alkylamine, an alkenylamine, an alkynylamine, an alkoxyamine and an amine of mono- or bicyclic aromatic or heteroaromatic moieties, any of which is optionally substituted with at least one group other than an acidic group. The resin material may conveniently be in a packed or a fluidised or expanded bed.

WO 01/58924 A2



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- without international search report and to be republished upon receipt of that report

NOVEL RESIN MATERIALS AND THEIR USE FOR RECOVERING PROTEINS OR PEPTIDES

5 FIELD OF INVENTION

The present invention relates to the field of recovering target proteins or peptides from an aqueous medium by contacting the medium containing the target protein or peptide with a resin that is capable of selectively binding the protein. Specifically, there is disclosed a
10 process of recovering milk clotting enzymes such as chymosin, and other proteins or peptides using novel resin materials.

TECHNICAL BACKGROUND AND PRIOR ART

15

Several techniques for recovering target proteins or peptides from aqueous media are available. Such techniques include e.g. ion exchange chromatography, hydrophobic interaction chromatography (HIC) and affinity chromatography. Recently, so-called mixed mode chromatographic resins have become available. This type of resins effects binding
20 of a target molecule under hydrophobic conditions and effects desorption or elution of the target molecule under electrostatic (ionic) or hydrophilic conditions. A recognised problem associated with currently available mixed mode resins is that binding efficiencies of less hydrophobic target molecules to the resin is not very high unless a high salt concentration is used in the aqueous medium containing the target molecule. Another problem with
25 mixed mode resins as it is mentioned in US 5,652,348 is that it may be required to apply a high ligand density (concentration) on the mixed mode chromatographic resin.

Other resin materials are described in the art including the resins as disclosed in WO 96/00735. This application discloses resins useful for the binding of a selected protein or
30 peptide, particularly from an aqueous medium such as a fermentation broth, by hydrophobic interactions between the resin and the selected protein or peptide. The resin is characterised as containing ionisable ligands and/or functionalities which are uncharged at the pH of binding the target protein or peptide. However, in the method as described a high ligand density is claimed as needed for optimal binding and furthermore, selected
35 proteins only bind to the resins when the resin is uncharged. This emphasises that the

resin material binds proteins due to hydrophobic interaction resulting in low binding capacities.

Another method is disclosed for the purification of Chymosin (US 5,215,907) by
5 hydrophobic interaction to phenylsepharose resin. Although, the method describes the use of a specific resin for the purification of the protein the result of the method as described is a very low recovery of the protein.

Yet another implication of binding to uncharged resin materials is that the pKa of the resin
10 must be lower than the loading pH of the solvent containing the target protein. The irreversibly inactivation of some proteins e.g. chymosin (Foltmann, B. 1959 Acta. Chem. Scand. 13, 1927-1942.) at neutral pH makes this a serious problem in selection of suitable resins.

15 In spite of the availability of this multiplicity of general techniques for separating and purifying target molecules such as proteins and peptides from aqueous media, it is generally recognised in the art that when a specific target molecule in a particular aqueous medium is to be recovered at a desired high efficiency, generally available techniques rarely, if ever, provides optimum recovery efficiency for the selected specific
20 target compound.

Accordingly, there is a continuing need to design novel recovery techniques or to adapt available techniques whenever the recovery of a specific target compound in a particular aqueous medium is to be optimised.

25

The present invention provides such an improved method for recovering target proteins or peptides from aqueous media. The method has proven to be particularly effective in the recovery of chymosin from aqueous media including fermentation media and aqueous extracts containing the chymosin. The invention is based on the discovery that a mixed
30 mode chromatographic resin comprising a solid support matrix having covalently bound thereto a ligand comprising an amine group is highly efficient for recovering chymosin.

In the present invention the ligands have been carefully selected, that have low ligand densities and are capable of binding the target protein with high capacity under conditions

where the resin is charged or partially uncharged. Thereby, the above mentioned problems of existing methods has been overcome.

5 SUMMARY OF THE INVENTION

Accordingly, in a first aspect there is provided a process for recovering a target protein having milk clotting activity from an aqueous medium containing such a protein, the method comprising the steps of:

10

- (a) contacting said medium with a resin material under conditions permitting the target protein to bind to the resin material, said resin material comprising a solid support matrix and, covalently bound to the matrix, a ligand that is capable of binding the protein, said ligand is selected from the group consisting of (i) benzylamine or a derivative thereof; (ii) 15 an alkylamine, including an alkylamine having a C₁₋₁₂ alkyl group having 1-12 carbon atoms which may be straight or branched or cyclic, such as e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, cyclopentyl, cyclohexyl or decalinyl, said alkyl group optionally being substituted with at least one group other than an acidic group; (iii) an alkenylamine, including a C₂₋₁₂ 20 alkenyl group including a mono-, di- or polyunsaturated alkyl group with 2-12 carbon atoms which may be straight, branched or cyclic and in which the double bond(s) may be present anywhere in the chain or the ring(s), said alkenyl group optionally being substituted with at least one group other than an acidic group; (iv) an alkynylamine, including a C₂₋₁₂ alkynyl group defined essentially as for the alkenylamine, including an 25 alkynyl group that is substituted with at least one group other than an acidic group; (v) an alkoxyamine with an alkoxy group that is optionally substituted with at least one group other than an acidic group; and (vi) an amine of mono- or bicyclic aromatic or heteroaromatic moities, optionally substituted with at least one group other than an acidic group; and (b) eluting the protein from the resin material.

30

- In a further aspect the invention pertains to a chromatographic resin material comprising a solid support matrix and, covalently bound to the matrix, a ligand that is capable of binding a target protein or peptide, said ligand is selected from the group consisting of (i) benzylamine or a derivative thereof; (ii) an alkylamine, including an alkylamine having a 35 C₁₋₁₂ alkyl group having 1-12 carbon atoms which may be straight or branched or cyclic,

such as e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, dodecyl, cyclopentyl, cyclohexyl or decalanyl, said alkyl group optionally being substituted with at least one group other than an acidic group; (iii) an alkenylamine, including a C₂₋₁₂ alkenyl group including a mono-, di- or polyunsaturated alkyl group with
5 2-12 carbon atoms which may be straight, branched or cyclic and in which the double bond(s) may be present anywhere in the chain or the ring(s), said alkenyl group optionally being substituted with at least one group other than an acidic group; (iv) an alkynylamine, including a C₂₋₁₂ alkynyl group defined essentially as for the alkenylamine, including an alkynyl group that is substituted with at least one group other than an acidic group; (v) an
10 alkoxyamine with an alkoxy group that is optionally substituted with at least one group other than an acidic group; and (vi) an amine of mono- or bicyclic aromatic or heteroaromatic moieties, optionally substituted with at least one group other than an acidic group.

15 In a still further aspect the invention relates to a process of recovering a target protein or peptide from an aqueous medium containing the target protein, the method comprising contacting the aqueous medium with the resin material of the invention under conditions where the target protein or peptide binds to the resin, and changing the conditions such that the target protein or peptide is eluted from the resin.

20

DETAILED DISCLOSURE OF THE INVENTION

It is one major objective of the present invention to provide a process for recovering a
25 target protein having milk clotting activity from an aqueous medium containing such a protein.

As used herein the expression "protein having milk clotting activity" refers to any enzyme including proteases that causes milk to clot. Such enzymes are widely used in the
30 manufacture of cheese and are also generally referred to as rennets (primarily milk clotting enzymes of animal origin) and microbial coagulants. The major sources of milk clotting enzymes are animal tissues and micro-organisms naturally producing proteases having milk clotting activity. The major animal rennet enzyme is chymosin (EC 3.4.23.4) an acidic protease that occurs in the stomach where it is excreted as a precursor,
35 prochymosin, that can be activated at pH below 5. Also pepsin (EC 3.4.23.1-3) that is

secreted from the gastric mucous membrane as a nonactive proenzyme, pepsinogen, which is activated by the action of the stomach acid, is used as rennet. Additionally, a wide range of micro-organisms, bacteria and filamentous fungi, naturally produce proteases having milk clotting activity. Thus, several *Bacillus* species are sources of such enzymes. Among filamentous fungi, at least the following species are known to produce rennet enzymes: *Rhizomucor pusillus*, *Rhizomucor miehei* and *Cryphonectria parasitica*. Preparations of such microbial milk clotting enzymes are provided as crude or at least partially purified fermentates of the source organisms. Furthermore, it is contemplated that plant extracts which causes milk clotting is also encompasses by the process of the present invention. Several plant extracts causing milk clotting are described in the art including extraction of the milk clotting enzymes from *Cynara* spp.

In recent years, methods have been developed to produce chymosin recombinantly by inserting a gene coding for the enzyme into suitable microbial host cells and cultivating the host cells under conditions where the gene is expressed, and recovering the enzyme from the fermentation medium (fermentate). A range of host cells for that purpose have been described such as e.g. bacterial strains of *E. coli* and *Bacillus* species, strains of yeast species include *Kluyveromyces lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, strains of filamentous fungi including e.g. *Aspergillus* species, *Mucor* species or *Rhizomucor* species. The recovery of such recombinantly produced milk clotting enzymes is also encompassed by the present invention.

The process of the invention for recovering from an aqueous medium a target protein as defined above that has milk clotting activity comprises the step of contacting the aqueous medium with a mixed mode chromatographic resin material under conditions permitting the target protein to bind to the resin material. The resin material of the invention comprises a solid support matrix and, covalently bound to the matrix, a ligand as defined hereinbefore that is capable of binding the protein. The term "solid support matrix" refers to the solid backbone material of the resin which contains reactive functionality permitting covalent attachment of the ligand to said backbone material.

The backbone material may be inorganic such as e.g. silica, or organic. Organic backbone materials which are useful herein include as examples cellulose and derivatives hereof, agarose, dextran, polymers such as e.g. polyacrylates, polystyrene, polyacrylamide, polymethacrylate, copolymers. Additionally, ter- and higher polymers can

be used provided that at least one of the monomers contains a reactive functionality in the resulting polymer.

Reactive functionalities of the solid support matrix permitting covalent attachment of the
5 ligand group are well known in the art and include e.g. hydroxyl, carboxyl, thiol and amino.

As used herein, the term "ligand" refers to a group consisting of a selected amine as defined herein, and a spacer arm for covalently attaching the ligand to the solid support matrix wherein the amine is preferably capable of being electrostatically charged at one
10 pH and electrostatically uncharged at another pH. The spacer arm can be any group or substituent which is capable of covalently attaching the selected amine to the solid support matrix. Such spacer arms are well known in the art and include e.g. alkylene groups, aromatic groups, alkylaromatic groups, amido groups, amino groups, urea groups, carbamate groups, $-R_1-Y-R_2$ -groups where R_1 and R_2 are alkylene groups and Y
15 is e.g. oxygen or sulfur. One example of a useful spacer arm is epichlorhydrin.

The aqueous medium containing the target protein is contacted with the resin of the invention under conditions permitting the target protein to bind to the resin material. The contact is typically brought about by loading the aqueous medium onto a chromatographic
20 column containing a bed of the resin material. The bed may be a packed bed or an expanded bed or any other bed form which is suitable for the intended purpose. When an expanded bed mode is used, the loading is conveniently made by pumping the medium onto the column either from the bottom or onto the top of the column. The flow rate depends on the volume of the bed and the amount of resin material in the column. A
25 typical flow rate is in the range of 1-20 cm/min such as 5-10 cm/min, e.g. 7.5 cm/min. Such a rate causes the bed of resin material to become fluidised, thus creating an expanded bed.

In useful embodiments, the ligand that binds the target protein is selected so as to obtain
30 that the ligand, under the conditions permitting the target protein to bind to the resin material, can be electrostatically charged or uncharged depending on the buffer pH. Prior to loading the aqueous medium onto the column, the resin material is typically equilibrated to the pH conditions at which the binding of the target protein occurs. The equilibration step is typically carried out by applying a buffer at a pH in the range of 3-10
35 such as in the range of 5-7.

The pH of the aqueous medium is e.g. pre-adjusted to a pH such as in the range of 3-10 including the range of 5-7. It has been found that the resin materials of the invention are highly effective even at a relatively low density. Thus, it was found that a very high recovery efficiency for chymosin can be achieved by using a resin material that has a concentration (density) of ligand which is at the most 150 μmol per ml of the settled resin material, such as at the most 100 $\mu\text{mol}/\text{ml}$ or even at the most 75 $\mu\text{mol}/\text{ml}$.

In preferred embodiments, the process of the invention recovers at least 50% of the total amount of target protein initially present in the aqueous medium, including at least 60%, 70%, 80% or 90% recovery. Even higher recovery rates have been found, such as at least 92.5%, 95%, 97.5% or at least 99%.

The process of the invention for recovering milk clotting enzymes can be used for any of such enzymes as defined above. Thus, the process includes processes wherein the aqueous medium containing the target protein is a microbial fermentation medium, including a medium that has been used for cultivating a recombinant micro-organism capable of expressing a milk clotting enzyme of animal, plant or microbial origin, or an aqueous extract of an animal tissue material. Particularly interesting milk clotting target protein include chymosin, pro-chymosin, pre-pro-chymosin and pepsin. In this context, such animal enzymes can be derived from any animal species naturally producing the enzymes, including a ruminant species such as bovine species, sheep or goats, pigs and camels.

As mentioned above, the enzymes having milk clotting activity can be produced recombinantly e.g. in host cells of fungal species and bacterial species expressing the enzyme. Accordingly, the aqueous medium used in the present process can be a fermentation medium of such recombinant host cells including filamentous species such as *Aspergillus* species, *Rhizomucor* species, *Penicillium* species, and yeast species including *Pichia* species, *Hansenula* species, *Saccharomyces* species and *Kluyveromyces* species. In this context, suitable bacterial host cell species also include *Bacillus* species and *E. coli*.

In one preferred embodiment, the solid support matrix is in the form of composite particles comprising a low density component and a high density component. Such particles are disclosed in co-owned WO 92/00799 which is hereby incorporated by reference.

Examples of materials which can be used in such particles as the low density component include hollow glass particles, agarose, cellulose and synthetic polymers such as those mentioned above. As the high density component may be used a material e.g. selected from solid glass particles, ceramic particles and metal particles. The advantages of using
5 such composite solid support matrix materials include that it is possible, by selecting the appropriate ratio between the high density and the low density components, to provide resin materials of the invention having a density that is specifically adapted to the specific requirements defined by the target protein and the aqueous medium containing it. Thus, resin materials that are useful in the present invention may be provided which have a
10 density in the range of 1.01 to 5.0, e.g. in the range of 1.1 to 2.0, 1.2 to 1.8 or 1.3 to 1.7. It is also possible to provide resins having a density below 1.0 such as a density in the range of 0.5 to 0.99 e.g. in the range of 0.6 to 0.9 including the range of 0.7 to 0.8.

The present process of recovering a protein having milk clotting activity is useful for
15 processing aqueous media in large scale volumes under industrial manufacturing conditions. Thus, the process is applicable as a process where the resin material, e.g. in an expanded bed mode, is contained in a column having a total volume of 100 litres or more, such as at least 200 litres, or at least 500 litres, e.g. 1000 litres or even several thousand litres.

20

In a more specific embodiment, the process of recovering a target protein having milk clotting activity comprises one or more cycles each comprising at least one of the following steps: (i) providing an expandable (fluidisable) bed of the resin material in a chromatographic column at a settled bed height of above 20; (ii) equilibrating the resin
25 material at a pH in the range of 3-10; (iii) loading the aqueous medium onto the column at a linear rate which is in range of 5-10 cm/min to bind the target protein; (iv) washing the loaded column using a washing buffer having a pH in the range of 3-10; (v) eluting the bound target protein from the column by applying onto the column a buffer having a pH below the pI of the target protein, typically a buffer of pH < 7, e.g. < 6, < 5 or < 4, and (vi)
30 regenerating the column under alkaline conditions. Such a process is useful for recovering chymosin and preferably, a selected resin is used that has a chymosin binding capacity of at least 100 International Milk Clotting Units (IMCU)/ml of settled resin, such as at least 1000 IMCU/ml of settled resin, including 5000 IMCU/ml of settled resin, such as 7,500 IMCU/ml of settled resin including at least 10,000 IMCU/ml. A presently preferred ligand
35 for recovering chymosin is benzylamine or a derivative thereof.

It may be preferred to carry out the above process using two chromatographic columns loaded with resin material according to the invention, where the two columns are serially connected. In such an embodiment, the first column is overloaded, i.e. the volume of aqueous medium applied to the column exceeds the maximum binding capacity of the resin material, in order to obtain the highest possible concentration of purified chymosin in the affluent from the first column. The target protein that does not bind to the first column due to the overloading will be bound in the second column. When the first column is fully loaded, the columns are disconnected. The first column is washed, eluted, regenerated and pH adjusted. Then the first column is placed in series after the second column and the second column can now be overloaded with chymosin. Repeated cycles are carried out until substantially all target protein is recovered.

In a further aspect, the invention relates to a selected chromatographic resin material as defined hereinbefore comprising a solid support matrix and, covalently bound to the matrix, a ligand that is capable of binding a target protein or peptide. It is contemplated that such a ligand is useful in a process of recovering a target protein or peptide from an aqueous medium containing the target protein, the method comprising contacting the aqueous medium with the resin material under conditions where the target protein or peptide binds to the resin, and changing the conditions such that the target protein or peptide is eluted from the resin. In one useful embodiment of such a general method, the ligand that is capable of binding a target protein or peptide is benzylamine including derivatives thereof. Target proteins or peptides that can be recovered by such a process include pharmaceutically active proteins or peptides including as examples, peptide hormones, insulin and cytokines, and enzymes not having milk clotting activity such as e.g. other proteases, lipases, phospholipases, carbohydrate degrading enzymes including enzymes that degrade disaccharides and oligosaccharides including starch, cellulose and hemicellulose, which enzymes are typically produced by using recombinant host cells expressing the protein or peptide.

When the processes of the invention is carried out in an expanded bed mode, the column containing the bed may be provided with means for agitating at least part of the fluidised bed or other means for obtaining an even distribution of the particles making up the fluidised bed and thus preventing the occurrence of turbulence or channel formation in the bed. Typically, such agitation means or other means such as a distributor means, e.g. a

perforated plate, may be provided at the bottom of the column containing the resin material.

The invention is further illustrated in the following example and the drawings, where

5

Fig. 1 is a schematic diagram of an Expanded Bed Adsorption (EBA) set-up including the EBA standard conditions used during loading, washing, elution, cleaning-in-place (CIP) and the equilibration step. RV: resin (settled bed) volumes;

10 Fig. 2. is a graph showing the recovery yield for chymosin and the binding capacity for chymosin of MIMO™ 1300 (Upfront Chromatography, Copenhagen, Denmark) (resin with benzylamine as the ligand), respectively vs. the resin bed height at a linear velocity $v = 7.5$ cm/min;

15 Fig. 3 shows the recovery for recombinant camel Chymosin;

Fig. 4 Represents a schematic illustration of the EBA set-up for purification of Chymosin and pepsin from calf and ox. extracts including conditions used during load, wash, elution, CIP and the equilibration phase;

20

Fig. 5 illustrates the recovery for animal rennet coagulants using MIMO™1300

Fig. 6 is a graph showing results of a binding study of chymosin to MIMO™1300 at different pH values;

25

Fig. 7 is a graph illustrating the titration of MIMO™1300 resin with the Benzylamine ligand, Bold line dV/dpH . Fine line ml applied 0.1 M NaOH;

Fig. 8 is a graph illustrating the titration of resin with Octylamine D ligand, Bold line
30 dV/dpH . Fine line applied ml 0.1 M NaOH; and,

Fig. 9 is a graph illustrating the titration of resin with Morpholino D ligand, Bold line dV/dpH . Fine line applied ml 0.1 M NaOH.

35

EXAMPLE 1

Recovery of chymosin from a fermentation medium

- 5 In this experiment, a batch of a fermentate produced by cultivating a recombinant strain of *Aspergillus awamori* expressing bovine chymosin was filtered to substantially remove the fungal biomass and cell debris. The pH of the filtrate was adjusted to about 2. This crude chymosin-containing filtrate was used as the starting material in a recovery process cycle as described in the following (see Fig. 1). Prior to the recovery process, the pH of the
10 acidic filtrate was adjusted to a pH of about 6.0 using 27% (w/w) NaOH.

The chymosin was recovered from the thus neutralised filtrate using a chromatographic column containing a bed of MIMOTM1300 resin at a settled bed height of about 55 cm. Under the conditions used the resin had a chymosin binding capacity of about 9000 IMCU
15 of chymosin per ml of settled resin. The binding capacity and yield increased with increasing bed high of the resin material as seen in figure 2.

Prior to loading the filtrate onto the column, the resin bed was equilibrated in order to adjust to the pH used during loading. The equilibration was made by applying 25 mM
20 sodium phosphate buffer, pH 5.5.

The loading step (step 1) was carried out by pumping the filtrate into the column at the bottom at a linear flow rate of about 7.5 cm/min and the loading of the column was continued until the binding capacity of the resin bed had been reached or even exceeded,
25 i.e. up to 150% such as 135% of the binding capacity.

Following the loading step, the column was washed to remove any unbound substances from the column using 4 resin (settled) volumes (RV) of 25 mM sodium phosphate buffer, pH 5.5 (step 2).
30

In a subsequent step, the bound chymosin was eluted (step 3) by applying 4 RV of 150 mM sodium phosphate buffer, pH 2.5 onto the previously washed column.

After the elution step, the resin was subjected to a regeneration (or CIP) step (step 4)

to remove remaining substances from the starting material that had not been removed in the elution step. This step was carried out by applying 4 RV of 1 M NaOH (pH > 12) onto the column. In a final step 5, the thus regenerated resin of the regenerated column was subjected to an equilibration step using 4 RV of 250 mM sodium phosphate buffer, pH 5.5.

5

After this equilibration step the column was ready to be used in a further recovery process cycle such as a cycle as described above.

10 EXAMPLE 2

Purification of recombinant camel chymosin from broth of *Aspergillus awamori* using expanded bed absorption

- 15 In this experiment, The recombinant *Aspergillus awamori* strain expressing the camel coagulant was grown in a complex nutrient medium in a fermentor. After end fermentation the fermentate was filtered to remove the fungal biomass and cell debris. pH of the clear filtrate was subsequently adjusted to pH about 2. This crude filtrate containing the camel Chymosin was used as starting material in the recovery process shown in the figure (Fig. 20 1). In addition, prior to the recovery process pH of the filtrate was adjusted to approx. pH 6 using 27% (w/w) NaOH.

An expanded bed semi-pilot column (2 cm diameter, 200 cm height) was filled to 70 cm (245 ml) of MimoTM1300 resin. Under the condition used the resin had a dynamic binding 25 capacity of about 5000 IMCU/ml settled resin.

Before loading the filtrate onto the column, the resin was expanded at 7.5 cm/min linear flow rate in equilibration buffer using 25 mM NaPO₄ buffer, pH 6. At the same flow rate filtrate was loaded (Fig. 1, step 1) onto the column and loading was continue until the 30 binding capacity of the resin had been reached or even exceeded.

Following the loading step the resin was then washed (Fig. 1, step 2) with equilibration buffer in order to remove impurities and weak bound substances from the column using 2-3 RV buffer. In the subsequently step (Fig. 1, step 3) camel coagulant was eluted from 35 the resin by applying 4 RV of 122 mM NaPO₄ ; pH 2.5 buffer.

In the following step (Fig. 1, step 4) the resin was subjected to regeneration (or CIP) in order to remove components from the filtrate that had not been removed during the elution step. 5 RV of 1 M NaOH was applied onto the column for the regeneration of the resin. Finally, the resin was subjected to an equilibration step (Fig. 1, step 5) using 3 RV of MQ-water and 6 RV of equilibration buffer. After step 5 the resin was ready to be used in a further recovery cycle as describe above.

The purification of recombinant camel Chymosin was successfully repeated in 5 purification cycles with recoveries ranging from 85% up to 93% (Fig. 3).

10

EXAMRLE 3

Purification and separation of Chymosin and Pepsin from calf and Ox. stomach (animal rennet)

15

The following example describes the purification and separation of animal rennet i.e. Chymosin and pepsin from calf and ox. stomach.

20 The crude extract used in the process was prepared from a saline extraction at neutral pH of animal stomachs (calf or adult bovine). After end extraction the extract was filtered to remove insoluble particles, biomass and cell debris. The extract containing primary inactive enzymes was subsequently activated adjusting pH to about 2. Coagulants found in the activated animal rennet extract consisted of Chymosin i.e. at least six variants of pl 25 4.6 - 5.0, mwt 35000, Pepsin, five to seven variants (phosphorylations) of approx. pl 1.6 - 2.0, mwt 35000 and Gastricsin, a minor component, approx. pl 3.5 - 3.8, mwt 35000. Chymosin constituted 20-80%, pepsin of 15-80% and gastricsin 1-5% of the total activity (depending on the type of stomach). Activated extract was used as starting material in the recovery process shown in the figure (Fig. 4).

30

An expanded bed semi-pilot column (2 cm diameter, 200 cm height) was filled to 50 cm (175 ml) of MimoTM1300 resin. Before loading the extract onto the column, the resin was expanded at 5.0 cm/min linear flow rate in equilibration buffer using 20 mM H₃PO₄ buffer, pH 5.8. At the same flow rate the rennet extract was loaded (Fig. 4, step 1) onto the

column and loading was continue until the binding capacity of the resin had been reached or even exceeded.

Following the loading step the resin was then washed (Fig. 4, step 2) with equilibration
5 buffer in order to remove impurities and weak bound substances from the column using
8-10 RV. In the subsequently step (Fig. 4, Elution I - step 3) primary Chymosin was eluted
from the resin by applying 6 -7 RV of 150 mM NaPO₄ ; pH 3.0 buffer, followed by one
further elution step (Fig. 4, Elution II - step 4) where primary pepsin was desorbed from
the resin using 6 -7 RV of 50 mM HCl.

10

After elution the resin was subjected to regeneration (Fig. 4, step 5) in order to remove
components from the extract that had not been removed during the elution step. 7-RV of
1 M NaOH was applied onto the column for the regeneration of the resin. Finally, the resin
was subjected to an equilibration step (Fig. 4, step 6) using 3 RV of MQ-water and 6 RV
15 of equilibration buffer. After step 6 the resin was ready to be used in a further recovery
cycle as describe above.

The purification of animal rennet coagulants was successfully repeated in 7 (5
experiments where Chymosin and pepsin were separated and 2 experiments with no
20 separation) purification cycles with recoveries ranging from 72% up to 88% (Fig. 5).

EXAMPLE 4

25 Binding study of Chymosin to MimoTM1300 at different pH values

In the present experiment the recombinant *Aspergillus awamori* strain expressing the
coagulant was grown in a complex nutrient medium in a fermentor. After end fermentation
the fermentate was filtered to remove the fungal biomass and cell debris. pH of the clear
30 filtrate was subsequently adjusted to pH about 2. This crude filtrate containing the
coagulant was used as starting material in the binding study of chymosin to MimoTM1300
at different pH values (Fig. 6). Prior to the recovery process pH of the filtrate was adjusted
to pH 4.5, 5.0, 5.5 and 6.0, respectively.

An expanded bed semi-pilot column (2 cm diameter, 200 cm height) was filled to 70 cm (245 ml) of MimoTM1300 resin. Before loading the filtrate onto the column, the resin was expanded at 7.5 cm/min linear flow rate in equilibration buffer using 25 mM NaPO₄ buffer. At the same flow rate, filtrate adjusted to the desired pH value was loaded (Fig. 1, step 1) 5 onto the column. Loading (approximately 10500 IMCU/ml settled resin) was continued until the binding capacity of the resin had been reached or even exceeded.

Following the loading step the resin was then washed (Fig. 1, step 2) with equilibration buffer in order to remove impurities and weak bound substances from the column using 10 2-3 RV buffer. In the subsequently step (Fig. 1, step 3) chymosin was eluted from the resin by applying 4 RV of 122 mM NaPO₄ ; pH 2.5 buffer. In the following step (Fig. 1, step 4) the resin was subjected to regeneration (or CIP) in order to remove components from the filtrate that had not been removed during the elution step. 5 RV of 1 M NaOH was applied onto the column for the regeneration of the resin. Finally, the resin was 15 subjected to an equilibration step (Fig. 1, step 5) using 3 RV of MQ-water and 6 RV of equilibration buffer. After step 5 the resin was ready to be used in a further recovery cycle as describe above.

The purification of recombinant chymosin with respect to binding capacity and percentage 20 of chymosin found in the run-through fraction at the different load pH values are shown in Figure 8. From Figure 8 it follows that the binding of chymosin onto the resin is possible at all measured pH values. The binding capacity, however, is reduced with decreasing pH, likely a result due to the reduction in the electrostatic interaction between Chymosin (pI 4.5) and the ligand (pKa 7) responsible for the biospecific interaction between Chymosin 25 and the MimoTM1300 resin. Hence, the resin is capable of binding the coagulant under condition where the resin is more than 50% charged during loading.

EXAMPLE 5

30

Feasibility study of *Rhizomucor miehei*-protease purification by MimoTM1300 resin.

In this example a milk coagulating enzyme was manufactured by submerged fermentation of the fungus *Rhizomucor*. The active milk clotting enzyme is *Rhizomucor miehei* protease 35 (EC 3.4.23.23) which belongs to the aspartyl proteases. The small scale study described

in the following was performed to clarify whether the MimoTM1300 resin was feasible for purification of the *Rhizomucor miehei* protease.

A column of 10 ml MimoTM1300 packed in a 1.5 x 12 cm Econo-Pac column (BioRad, Hercules, CA) was equilibrated with 2 resin volumes (RV) of 80 mM sodium acetate buffer pH 5.5. The solvent flow in the column was approx. 1-2 ml/min, driven by gravity. The MimoTM1300 column was loaded with 18 ml of filtered fermentation medium, preserved with 15% NaCl and 0.4% sodium benzoate (Chr. Hansen A/S, Hørsholm, Denmark). After loading the column was washed with 2 RV of equilibration buffer and eluted with 2 RV of 25 mM Sodium phosphate pH 2.5. Samples were collected during loading, washing and elution of the column. The samples were collected in fractions according to the milk clotting activity determined. The fraction's activity and percentage recovery are presented in the Table below.

Table 1. Recovery of milk clotting units, in *Rhizomucor miehei* protease purification by MimoTM1300 resin.

Fraction	Volume, ml	Activity, IMCU	% Recovery
Fermentate	18	31.500	-
Run trough	18	< 36	.0
Wash	20	1.900	6 %
Eluate 1	6	< 12	
Eluate 2	10	19.859	63%

Conclusion.

20

The MimoTM1300 resin is very suitable for purification of *Rhizomucor miehei* protease. An improved recovery, than the obtained 63% of the loaded activity demonstrated in the present experiment, can be achieved when larger resin bed heights are applied (as seen in Fig. 2). Furthermore, since no optimisation of flow, pH and conductivity during loading have been done in this experiment, significant better performance is expected to appear at optimised conditions.

25

EXAMPLE 6

Isolation of chymosin/pepsin from ox stomach extract using chromatography.

5 Epoxy activated 6 % agarose was coupled with the following amino ligands:

4-(2-aminoethyl)morpholine

1,8-diaminooctan

Octylamine

10 2-(2-aminoethyl)pyridine

2-aminopyridine

N-phenyl-ethylendiamine

1-phenyl-5-mercapto tetrazol

2-mercaptopyrimidine

15 Benzylamine

The final ligand concentration of the different matrices was determined by titration with 0.1 N HCl, see results in table 2 below.

Table 2. Illustrate the ligand concentrations.

Ligand	Ligand concentration, $\mu\text{mol/g}$ suction drained matrix
4-(2-aminoethyl)morpholine	59
1,8-diaminooctan	61
Octylamine	62
2-(2-aminoethyl)pyridine	67
2-aminopyridine	25
N-phenyl-ethylendiamine	40
1-phenyl-5-mercapto tetrazol	40
2-mercaptopyrimidine	20
Benzylamine	63

20

Materials and methods.

Extract from ox. stomach containing pepsin and chymosin was activated by adjusting pH to 2.2 with 1 M HCl. After 30 minutes the pH was increased to 5.7 with 1 M NaOH. The

extract was clarified by the use of filter help. The activity of the extract was determined to be 25 IMCU/ml extract.

Each matrix was equilibrated with tap water. 0.5 ml of the respective matrices was
5 incubated for 1 hour with 50 ml of the clarified extract (pH 5.7).

After incubation the matrix was collected and transferred to a chromatographic column.

The non-bound material was washed out of the matrices with tap water.

The bound proteins were eluted by adding 50 mM HCl. The eluate was neutralised with 1 M NaOH.

10

Results.

The capacity (illustrated in table 3) of the different matrices was estimated by milk clotting assay on the supernatants after incubation with the matrices.

15

Table 3. Capacity of different ligands.

Ligand	Capacity
4-(2-aminoethyl)morpholine	+
1,8-diaminooctan	+++
Octylamine	+++
2-(2-aminoethyl)pyridine	++
2-aminopyridine	0
N-phenyl-ethylenediamine	+++
1-phenyl-5-mercapto tetrazol	0
2-mercaptopyrimidine	0
Benzylamine	+++

+++ bound more than 90 % of the applied enzyme

++ bound 50-90 % of the applied enzyme

+ bound 10-50 % of the applied enzyme

20 0 bound less than 10 % of the applied enzyme

Recovery of enzymes.

The amount of eluted enzymes from each matrix was estimated by milk clotting assay.

25 See results in table 4 below.

Table 4. Recovery of milk clotting enzymes.

Ligand	
4-(2-aminoethyl)morpholine	+++
1,8-diaminooctan	+
Octylamine	+
2-(2-aminoethyl)pyridine	+++
2-aminopyridine	-
N-phenyl-ethylenediamine	+++
1-phenyl-5-mercapto tetrazol	-
2-mercaptopyrimidine	-
Benzylamine	+++

- no results.

+ 0-25 % of the bound enzymes were recovered in the eluate.

+++ >90 % of the bound enzymes were recovered in the eluate.

5

EXAMPLE 7

Determination of ligand densities and pKa values of Benzylamine, Morpholinamine and

10 Octylamine resins.

Preparation of resin. The resin was rinsed in a glass filter funnel with 150 ml solution of 0.1 M NaOH, 0.1 M HCl and 1 M NaCl. Between each solution the resin was rinsed with degassed Milli-Q water (MQW). For titration, 5 g of resin was weighted into a 100 ml
 15 container and suspended in 30 ml MQW. The resin was titrated with 0.1 M NaOH on a Methrohm-716 DMS Titrino, using volume increments of 0.020 ml, tolerating 3 mV signal drift and equilibration time of 600 sec. Prior to titration, the 0.1 M NaOH solution was prepared from NaOH pellets and the resin suspension was pH adjusted with 100 µl 0.5 M HCl.

20

Results

Using the base consumption from the titration of the three resins the ligand densities were calculated and the following ligand densities were obtained: 36 µmol benzylamine/g resin,
 25 96 µmol 4-(2-aminoethyl)morpholine/g resin, and 35 µmol octylamine/g resin. The pKa

values were estimated from dV/dpH plotted as function of pH. Estimates of pK_a were 7.5, 5.5 and 7.7 for benzylamine resin, 4-(2-aminoethyl)morpholine resin and octylamine resin respectively. From the titration curves presented (Figs. 7, 8 and 9) it is obvious that a significant portion of the different resins will be charged if the resins are operated below

5 pH 7

CLAIMS

1. A process for recovering a target protein having milk clotting activity from an aqueous medium containing such a protein, the method comprising the steps of

5

contacting said medium with a resin material under conditions permitting the target protein to bind to the resin material, said resin material comprising a solid support matrix and, covalently bound to the matrix, a ligand that is capable of binding the protein, said ligand is selected from the group consisting of

10

(i) benzylamine;

(ii) an alkylamine, including an alkylamine having a C₁₋₁₂ alkyl group having 1-12 carbon atoms which may be straight or branched or cyclic, such as e.g. methyl, ethyl, propyl,

15 isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, cyclopentyl, cyclohexyl or decalanyl, said alkyl group optionally being substituted with at least one group other than an acidic group;

(iii) an alkenylamine, including a C₂₋₁₂ alkenyl group including a mono-, di- or

20 polyunsaturated alkyl group with 2-12 carbon atoms which may be straight, branched or cyclic and in which the double bond(s) may be present anywhere in the chain or the ring(s), said alkenyl group optionally being substituted with at least one group other than an acidic group;

25 (iv) an alkynylamine, including a C₂₋₁₂ alkynyl group defined essentially as for the alkenylamine, including an alkynyl group that is substituted with at least one group other than an acidic group;

(v) an alkoxyamine with an alkoxy group that is optionally substituted with at least one
30 group other than an acidic group; and

(vi) an amine of mono- or bicyclic aromatic or heteroaromatic moieties, optionally substituted with at least one group other than an acidic group, and

35 eluting the protein from the resin material.

2. A method according to claim 1 wherein, under the conditions permitting the target protein to bind to the resin material, a proportion of the ligand which is in the range of 5-100% is electrostatically charged.
- 5 3. A method according to claim 1 wherein the resin material has a ligand concentration which is at the most 150 μ mol per ml of resin material.
4. A method according to claim 1 wherein at least 90% of the total amount of target protein initially present in the aqueous medium is recovered.
- 10 5. A process according to claim 1 wherein the aqueous medium containing the target protein is selected from the group consisting of a microbial fermentation medium and an aqueous extract of an animal or plant tissue material.
- 15 6. A process according to claim 5 wherein the fermentation medium is a medium used for cultivating a recombinant micro-organism capable of expressing a milk clotting enzyme of animal origin, the cultivation is under conditions where the enzyme is expressed.
7. A process according to claim 6 wherein the milk clotting enzyme is selected from the
20 group consisting of chymosin, pro-chymosin, pre-pro-chymosin and pepsin.
8. A process according to claim 6 wherein the recombinant micro-organism is selected from the group consisting of a fungal species and a bacterial species.
- 25 9. A process according to claim 8 wherein the fungal species is selected from the group consisting of an *Aspergillus* species, a *Rhizomucor* species, a *Penicillium* species and a yeast species including a *Pichia* species, a *Hansenula* species, a *Saccharomyces* species and a *Kluyveromyces* species.
- 30 10. A process according to claim 1 wherein the target protein having milk clotting activity is derived from a microbial species including a *Bacillus* species.
11. A process according to claim 1 wherein the resin material is in the form of composite particles comprising a low density component and a high density component.

12. A process according to claim 11 wherein the low density component comprises a material selected from the group consisting of hollow glass particles, agarose, cellulose and a synthetic polymer.

5 13. A process according to claim 11 or 12 wherein the high density component comprises a material selected from the group consisting of solid glass particles, ceramic particles and metal particles.

14. A process according to claim 11 wherein the density of the composite particles is in
10 the range of 1.01 to 5.0.

15. A process according to claim 11 wherein the density of the composite particles is in the range of 0.5 to 0.99.

15 16. A process according to claim 1 wherein the ligand that is capable of binding the target protein is benzylamine or a derivative thereof.

17. A process according to claim 1 wherein the resin material is contained in a column having a total volume of 100 litres or more.

20

18. A process according to claim 1 wherein, under the conditions permitting the target protein to bind to the resin material, the ligand is essentially electrostatically uncharged and, under the conditions where the target protein is eluted, the ligand is electrostatically charged.

25

19. A process according to claim 1 wherein, under the conditions permitting the target protein to bind to the resin material, the ligand is essentially electrostatically charged and, under the conditions where the target protein is eluted, the ligand is electrostatically uncharged.

30

20. A process according to claim 1 comprising one or more cycles comprising the following steps:

(i) providing a bed of the resin material in a chromatographic column at a settled bed
35 height of above 20 cm,

(ii) equilibrating the resin material at a pH in the range of 3-10,

(iii) loading the aqueous medium onto the column at a linear rate which is in range of 3-10 cm/min to bind the target protein;

5

(iv) washing the loaded column using a washing buffer having a pH in the range of 3-7;

(v) eluting the bound target protein from the column by applying onto the column a buffer having a pH below the pI of the target protein, typically a buffer pH < 4, and

10

(vi) regenerating the column under alkaline conditions.

21. A process according to claim 1 or 20 wherein the resin material has a chymosin binding capacity of at least 5,000 IMCU/ml.

15

22. A process according to claim 20 wherein the ligand that is capable of binding the target protein is benzylamine or a derivative thereof.

23. A chromatographic resin material comprising a solid support matrix and, covalently bound to the matrix, a ligand that is capable of binding a target protein or peptide, said ligand is selected from the group consisting of

20

(i) benzylamine or a derivative thereof;

25 (ii) an alkylamine, including an alkylamine having a C₁₋₁₂ alkyl group having 1-12 carbon atoms which may be straight or branched or cyclic, such as e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, dodecyl, cyclopentyl, cyclohexyl or decalanyl, said alkyl group optionally being substituted with at least one group other than an acidic group;

30

(iii) an alkenylamine, including a C₂₋₁₂ alkenyl group including a mono-, di- or polyunsaturated alkyl group with 2-12 carbon atoms which may be straight, branched or cyclic and in which the double bond(s) may be present anywhere in the chain or the ring(s), said alkenyl group optionally being substituted with at least one group other than

35

an acidic group;

(iv) an alkynylamine, including a C₂₋₁₂ alkynyl group defined essentially as for the alkenylamine, including an alkynyl group that is substituted with at least one group other than an acidic group;

- 5 (v) an alkoxyamine with an alkoxy group that is optionally substituted with at least one group other than an acidic group; and

(vi) an amine of mono- or bicyclic aromatic or heteroaromatic moieties, optionally substituted with at least one group other than an acidic group.

10

24. A process of recovering a target protein or peptide from an aqueous medium containing the target protein, the method comprising contacting the aqueous medium with the resin material of claim 23 under conditions where the target protein or peptide binds to the resin, and changing the conditions such that the target protein or peptide is eluted

15 from the resin.

25. A process according to claim 24 wherein the ligand that is capable of binding a target protein or peptide is benzylamine or a derivative thereof.

- 20 26. A process according to claim 24 wherein the target protein or peptide is a pharmaceutically active protein or peptide.

27. A process according to claim 24 wherein the target protein or peptide is an enzyme not having milk clotting activity.

25

28. A process according to claim 24 wherein the resin material is an expanded fluidised bed contained in a chromatographic column.

29. A process according to claim 24 wherein resin material contained in the
30 chromatographic column is in a fluidised (expanded) bed state and the column is provided with means for agitating at least part of the fluidised bed.

1/9





Fig. 1


2/9

Impact of bed height on binding of chymosin

Capacity and yield versus settled bed height.

**Fig. 2.**

Recovery for camel chymosin



Semi-Pilot
Experiment

Fig. 3

4/9




Fig. 4

5/9

Recovery for animal rennet using Mimo1300-D




Fig. 5

6/9

Impact of load pH on binding of Chymosin.




Fig. 6

7/9




Fig. 7

8/9




Fig. 8

9/9




Fig. 9

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58924 A3

- (51) International Patent Classification⁷: C07K 1/00, B01D 15/08, B01J 20/00
- (21) International Application Number: PCT/DK01/00086
- (22) International Filing Date: 8 February 2001 (08.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PA 2000 00199 8 February 2000 (08.02.2000) DK
60/181.079 8 February 2000 (08.02.2000) US
- (71) Applicant (for all designated States except US): **UP-FRONT CHROMATOGRAPHY A/S** [DK/DK]; Lersø Parkallé 42, DK-2100 Copenhagen Ø (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LIHME, Allan, Otto, Fog** [DK/DK]; Furesøbakken 13, DK-3460 Birkerød (DK). **HANSEN, Marie, Bendix** [DK/DK]; Thurøvej 14, 1. th., DK-2000 Frederiksberg (DK). **BISGAARD-FRANTZEN, Hans** [DK/DK]; Sprogøvej 9, 3. th., DK-2000 Frederiksberg (DK). **RAHBK-NIELSEN, Henrik** [DK/DK]; Kirsebærlunden 1, DK-3460 Birkerød (DK).
- (74) Agent: **PLOUGMANN & VINGTOFT A/S**; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
2 May 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL RESIN MATERIALS AND THEIR USE FOR RECOVERING PROTEINS OR PEPTIDES

(57) Abstract: Processes for recovering a target protein having milk clotting activity including chymosin, and other target proteins or peptides from an aqueous medium containing such a protein using a resin material comprising a solid support matrix and, covalently bound to the matrix, a target protein binding ligand selected from benzylamine or a derivative thereof; an alkylamine, an alkenylamine, an alkynylamine, an alkoxyamine and an amine of mono- or bicyclic aromatic or heteroaromatic moieties, any of which is optionally substituted with at least one group other than an acidic group. The resin material may conveniently be in a packed or a fluidised or expanded bed.

WO 01/58924 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 01/00086

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K1/00 B01D15/08 B01J20/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K B01D B01J G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUNNAR HOUEN ET AL: "The primary structure and enzymic properties of porcine prochymosin and chymosin" INT. J. BIOCHEM. CELL BIOL., vol. 28, no. 6, 1996, pages 667-675, XP002901712	1-10, 17-21, 23,24
Y	page 668, column 2 --- -/-	11-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 October 2001

Date of mailing of the international search report

11. 01. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Carl- Olof Gustafsson

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 01/00086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BURTON S C ET AL: "One step purification of chymosin by mixed mode chromatography" BIOTECHNOL BIOENG, vol. 56, no. 1, 5 October 1997 (1997-10-05), pages 45-55, XP002901713 abstract page 46, "Reagents, matrices and equipment"; page 47, "Epoxide activated matrices"	1-10, 17-21, 23,24
Y	---	11-15
X	CHEMICAL ABSTRACTS, vol. 131, no. 23, 1999 Columbus, Ohio, US; abstract no. 308212, WONKYUNG K ET AL: "Direct purification of lysozyme from hen egg white using high density mixed mode adsorbent" XP002901714 abstract & J. MICROBIOL. BIOTECHNOL., vol. 9, no. 3, 1999, pages 292-296, ---	23-25,27
Y	WO 92 00799 A (KEM EN TEC AS) 23 January 1992 (1992-01-23) claims 1-25,33 ---	11-15
A	WO 90 15865 A (GENENCOR INT) 27 December 1990 (1990-12-27) abstract; claims ---	1-22
X	WO 96 09116 A (UNIV MASSEY) 28 March 1996 (1996-03-28) page 10, line 5 - line 23 page 26, line 21 - line 24 page 31, line 5 - line 8 page 39, line 20 -page 40, line 16	1-10, 17-21, 23,24, 26-29
Y	---	11-15
X	KENNY SPROULE ET AL: "New strategy for the design of ligands for the purification of pharmaceutical proteins by affinity chromatography" JOURNAL OF CHROMATOGRAPHY B, vol. 740, 2000, XP002901947 page 17 -page 33 page 19; table 1 ---	23-29
X	WO 90 14886 A (CENTRAL BLOOD LAB AUTHORITY) 13 December 1990 (1990-12-13) page 19, line 8 - line 9 ---	23,24, 26-29
	--- -/--	

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/DK 01/00086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 6 090 288 A (BERGLUND ROLF ET AL) 18 July 2000 (2000-07-18) column 6, line 55 - line 57 column 15, line 65 -column 16, line 40 column 3, line 25 - line 35 ---	23,24, 26-29
X	G HOUEN ET AL: "Affinity chromatography of thiol ester-containing proteins" JOURNAL OF CHROMATOGRAPHY A, vol. 799, 1998, pages 139-148, XP002901948 page 144 abstract ---	23,24, 26-29
X	G H SCHOLZ ET AL: "Salt-independent binding of antibodies from human serum to thiophilic heterocyclic ligands" JOURNAL OF CHROMATOGRAPHY B, vol. 709, 1998, pages 189-196, XP002901949 abstract page 191; table 1 -----	23,24, 26-29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 01/00086

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1 and 23 partially
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1 and 23 partially

Present claims 1 and 23 relate to an extremely large number of possible ligands. The wordings " branched or cyclic ", " being substituted with at least one group other than an acidic group ", " polyunsaturated alkyl groups ", " alkynylamine ", " alkynyl group defined essentially as for ", " alkoxyamine ", and " amine of mono- or bicyclic aromatic or heteroaromatic moieties " are very broadly formulated. It is also unclear what groups can be considered as " an acidic group ". Subgroups III-V are not exemplified in the description. The wording "substituted with at least one group other than an acidic group " is interpreted so as to not exclude the possibility of having acidic groups elsewhere in the ligands of claim 1 and 23. Further, the wordings of claim 1 and 23 would permit ligands including polyamines.

In fact, the claims contain so many options that a lack of clarity and conciseness within the meaning of Article 6 PCT arise to such an extent as to render a meaningful search of the claims impossible.

Consequently, the search has been carried out for those parts of the application which appear to be clear and concise, and has been focused on the ligands explicitly revealed in the description (example 6). The search has include ligands according to the general definitions only to a rather limited extent.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION: CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-29 (partially)

Invention 1: Chromatographic material and a process for the binding and recovery of proteins making use of the subgroup I binding ligand, benzylamine.

2. Claims: 1-29 (partially)

Invention 2: Chromatographic material and a process for the binding and recovery of proteins making use of subgroup II binding ligands, alkylamines.

3. Claims: 1-29 (partially)

Inventions 3-6: Chromatographic material and processes for the binding and recovery of proteins making use of subgroups III-VI as binding ligands.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/DK 01/00086

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9200799	A	23-01-1992	AT 143288 T 15-10-1996
			AT 143139 T 15-10-1996
			AT 185089 T 15-10-1999
			AU 659090 B2 11-05-1995
			AU 8219591 A 04-02-1992
			CA 2086752 A1 10-01-1992
			CA 2259061 A1 10-01-1992
			CA 2259062 A1 10-01-1992
			DE 69122271 D1 24-10-1996
			DE 69122271 T2 24-04-1997
			DE 69122393 D1 31-10-1996
			DE 69122393 T2 24-04-1997
			DE 69131670 D1 04-11-1999
			DE 69131670 T2 08-06-2000
			WO 9200799 A1 23-01-1992
			DK 538350 T3 06-10-1997
			DK 607998 T3 17-03-1997
			EP 0538350 A1 28-04-1993
			EP 0607998 A2 27-07-1994
			EP 0722771 A1 24-07-1996
			EP 0978311 A1 09-02-2000
			EP 0976447 A1 02-02-2000
			ES 2095944 T3 01-03-1997
			ES 2094572 T3 16-01-1997
			HU 67261 A2 28-03-1995
			JP 3168206 B2 21-05-2001
			JP 6505911 T 07-07-1994
			US 6043067 A 28-03-2000
			US 5866006 A 02-02-1999
			US 5935442 A 10-08-1999
WO 9015865	A	27-12-1990	US 5122467 A 16-06-1992
			AU 629656 B2 08-10-1992
			AU 5852290 A 08-01-1991
			CA 2058453 A1 14-12-1990
			DE 69018823 D1 24-05-1995
			DE 69018823 T2 07-12-1995
			DK 477277 T3 21-08-1995
			EP 0477277 A1 01-04-1992
			FI 100110 B1 30-09-1997
			JP 2974763 B2 10-11-1999
			JP 5500301 T 28-01-1993
			NO 914886 A 12-12-1991
			NZ 234058 A 28-07-1992
			WO 9015865 A1 27-12-1990
			US 5215908 A 01-06-1993
WO 9609116	A	28-03-1996	US 5652348 A 29-07-1997
			AU 683588 B2 13-11-1997
			AU 3621295 A 09-04-1996
			CA 2200735 A1 28-03-1996
			EP 0783366 A1 16-07-1997
			JP 10506987 T 07-07-1998
			WO 9609116 A1 28-03-1996
			NZ 293707 A 29-03-1999
WO 9014886	A	13-12-1990	US 5945520 A 31-08-1999
			AT 88375 T 15-05-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 01/00086

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9014886	A	AU 644801 B2	23-12-1993
		AU 5924390 A	07-01-1991
		CA 2057926 A1	09-12-1990
		DE 69001436 D1	27-05-1993
		DE 69001436 T2	28-10-1993
		DK 476038 T3	17-05-1993
		WO 9014886 A1	13-12-1990
		EP 0476038 A1	25-03-1992
		ES 2054361 T3	01-08-1994
		JP 7022702 B	15-03-1995
		JP 4506030 T	22-10-1992
		US 5304638 A	19-04-1994
US 6090288	A	18-07-2000	AU 713635 B2 09-12-1999
			AU 1818097 A 02-09-1997
			CA 2242927 A1 21-08-1997
			EP 0888157 A1 07-01-1999
			JP 2000504625 T 18-04-2000
			WO 9729825 A1 21-08-1997

THIS PAGE BLANK (USPTO)